mProX™ Human KLRC1 Stable Cell Line

Product Information

Target Family

Kinases/Enzyme

Target Protein Species

Human

Host Cell Type

HEK293;CHO-K1

Target Classification

Kinase Cell Lines

Target Research Area

Immunology Research

Related Diseases

Nk Cell Deficiency; Human Cytomegalovirus Infection

Gene ID

Human:3821

UniProt ID

Human:P26715

Product Properties

Biosafety Level

Level 1

Activity

Yes

Quantity

10⁶ cells per vial

Applications

KLRC1, also known as NKG2A or CD159A, is a gene that encodes a protein involved in immune response and regulation. Several studies have explored the applications of KLRC1 in different contexts. One study focused on patients who underwent liver transplantation and received immunosuppressive therapy, revealing that CD8+ NKG2A+ natural killer T (NKT) cells specifically expressed KLRC1 and played a crucial role in immune tolerance to liver transplantation. Another study investigated the role of KLRC1 in NK cells and found that it is involved in the regulation of metabolism, thermogenesis, and oxidative phosphorylation in NK cells. Additionally, KLRC1 knockout was shown to improve NK cell antitumor activity against solid tumors by overcoming HLA-E-mediated inhibition. Furthermore, a study in acute myeloid leukemia (AML) patients receiving immunotherapy found that a gene variant of NKG2A (rs1983526) was associated with improved outcome and enhanced NK cell effector function. Lastly, in individuals who did not generate an immune response to the hepatitis B vaccine, KLRC1 expression was found to be significantly higher in CD3highCD16lowKLRG1high NKT cells, suggesting a potential role in the immune response to the vaccine. Overall, these studies highlight the diverse applications of KLRC1 in immune response, transplantation, cancer immunotherapy, and vaccine response.

Protocols

Please visit our protocols page.

Customer Reviews

There are currently no Customer reviews or questions for mProX™ Human KLRC1 Stable Cell Line (S01YF-1023-PY153). Click the button above to contact us or submit your feedback about this product.

FAQ

chat Peyton Jones (Verified Customer)

How does KLRC1 knockout enhance NK cell antitumor activity? Aug 16 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

KLRC1 knockout can improve NK cell antitumor activity against solid tumors expressing HLA-E, suggesting its potential in NK cell therapy development. Aug 16 2022

chat Taylor Smith (Verified Customer)

What is the significance of KLRC1 in systemic lupus erythematosus? Sep 14 2022

chat Patrick Liam (Creative Biolabs Scientific Support)

KLRC1 mRNA expression is higher in patients with systemic lupus erythematosus, indicating its potential role in the disease. Sep 14 2022

Published Data

Fig.1 The variations in KLRC1 expression levels observed between the tumor tissue and neighboring normal tissue across all TCGA tumor types were noteworthy, revealing intriguing insights into the molecular distinctions associated with these malignancies.

Expression levels of human KLRC1 across various tumor types were assessed using data from the TCGA database via TIMER analysis (*p < 0.05, **p < 0.01, ***p < 0.001). Notably, KLRC1 expression exhibited a substantial decrease in the majority of tumors when compared to adjacent normal tissues, including breast invasive carcinoma, colon adenocarcinoma, liver hepatocellular carcinoma, LUAD, LUSC, PRAD, rectum adenocarcinoma, and uterine corpus endometrial carcinoma. In contrast, KLRC1 expression was markedly elevated in head and neck cancer, kidney renal clear cell carcinoma, and kidney renal papillary cell carcinoma in comparison to adjacent normal tissues.

Ref: Chen, Yongyuan, et al. "CD8+ T cells form the predominant subset of NKG2A+ cells in human lung cancer." Frontiers in immunology 10 (2020): 3002.

Pubmed: 32010126

DOI: 10.3389/fimmu.2019.03002

Research Highlights

Fang, Yuan. et al. "ScRNA-seq revealed disruption in CD8+ NKG2A+ natural killer T cells in patients after liver transplantation and immunosuppressive therapy" Immunity, inflammation and disease, 2023.
Liver transplantation (LT) is a highly effective treatment option for patients in both the short and long term. However, there are several challenges that still exist in the management of LT, including long-term immunosuppression and its associated side effects. One of the most common side effects is changes in the composition of the cellular immune system over time, which impacts the development of immune tolerance. Despite this, the dynamics of this process during immunosuppressive therapy have yet to be fully understood.
Fang, Yuan. et al. "ScRNA-seq revealed disruption in CD8+ NKG2A+ natural killer T cells in patients after liver transplantation and immunosuppressive therapy" Immunity, inflammation and disease, 2023.
Pubmed: 37773707 DOI: 10.1002/iid3.990

Feng, Juan. et al. "Proteomic Analysis by 4D Label-free MS-PRM Provides Insight into the Role and Regulatory Mechanisms of IL-25 in NK cells." Protein and peptide letters, 2023.
The role of NK cells in the immune response, immune surveillance, and metabolism regulation has been well-established. Their involvement in various diseases, including infectious diseases, cancer, obesity, and diabetes, has also been recognized. Among the IL-17 family, IL-25 stands out for its anti-inflammatory function. Studies have shown that it can regulate inflammation and metabolism through different immune cells. However, the specific role and regulatory mechanism of IL-25 in NK cells have yet to be fully elucidated.
Feng, Juan. et al. "Proteomic Analysis by 4D Label-free MS-PRM Provides Insight into the Role and Regulatory Mechanisms of IL-25 in NK cells." Protein and peptide letters, 2023.
Pubmed: 37702163 DOI: 10.2174/0929866530666230911164329